| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.1 | 0.06 |
| mRNA | Mdivi-1 | CTRPv2 | pan-cancer | AAC | -0.068 | 0.06 |
| mRNA | BI-2536 | GDSC1000 | pan-cancer | AAC | 0.097 | 0.06 |
| mRNA | ZSTK474 | GDSC1000 | pan-cancer | AAC | 0.057 | 0.06 |
| mRNA | BX-912 | GDSC1000 | pan-cancer | AAC | 0.055 | 0.06 |
| mRNA | GW843682X | CTRPv2 | pan-cancer | AAC | 0.064 | 0.07 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | 0.053 | 0.07 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.066 | 0.07 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.081 | 0.07 |
| mRNA | Bexarotene | FIMM | pan-cancer | AAC | -0.27 | 0.07 |